Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model

Soham Shukla,1 Dhvani Shah,2 Alan Martin,3 Nancy A Risebrough,4 Robyn Kendall,5 Claus F Vogelmeier,6 Isabelle Boucot,3 Lee Tombs,7 Leif Bjermer,8 Paul W Jones,3 Edward Kerwin,9 Chris Compton,3 François Maltais,10 David A Lipson,11,12 Afisi S Ismaila1,13 1Value Evidence and Outcomes, GSK, Collegevill...

Full description

Saved in:
Bibliographic Details
Main Authors: Shukla S, Shah D, Martin A, Risebrough NA, Kendall R, Vogelmeier CF, Boucot I, Tombs L, Bjermer L, Jones PW, Kerwin E, Compton C, Maltais F, Lipson DA, Ismaila AS
Format: article
Language:EN
Published: Dove Medical Press 2021
Subjects:
copd treatment
cost-effectiveness
umeclidinium
salmeterol
umeclidinium/vilanterol
Diseases of the respiratory system
RC705-779
Online Access:https://doaj.org/article/6ae2f1ee068e4003a1696cf3ce64229f
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/6ae2f1ee068e4003a1696cf3ce64229f

Similar Items